U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07896772) titled 'Anti-Mullerian Hormone in Breast Cancer Clinical Practice' on Oct. 20.
Brief Summary: This study aims to evaluate serum anti-Mullerian hormone (AMH) levels and complementary hormonal parameters, including follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), and free thyroxine (fT4), in women with breast cancer and healthy female controls.
The study will generate preliminary real-world data on AMH and related hormonal parameters and assess the feasibility of implementing AMH testing into routine clinical practice.
Study Start Date: Nov. 20, 2025
Study Type: OBSERVATIONAL
Condition:
Breast Cancer
Rec...